For medicines: For risks and side effects, read the package leaflet and ask your doctor or pharmacist
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Yes, a b12 injection is a prescription medication
As systemic metabolic function improves, secondary benefits such as enhanced muscle definition, improved skin tone, and overall physical refinement may be observed, reflecting improved cellular energy balance and reduced inflammatory burden
PARPs: Enzymes that help repair DNA damage, but use up large amounts of NAD+ in the process
